These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 28469082)

  • 1. CTLA4-Ig in combination with FTY720 promotes allograft survival in sensitized recipients.
    Khiew SH; Yang J; Young JS; Chen J; Wang Q; Yin D; Vu V; Miller ML; Sciammas R; Alegre ML; Chong AS
    JCI Insight; 2017 May; 2(9):. PubMed ID: 28469082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delayed Cytotoxic T Lymphocyte-Associated Protein 4-Immunoglobulin Treatment Reverses Ongoing Alloantibody Responses and Rescues Allografts From Acute Rejection.
    Young JS; Chen J; Miller ML; Vu V; Tian C; Moon JJ; Alegre ML; Sciammas R; Chong AS
    Am J Transplant; 2016 Aug; 16(8):2312-23. PubMed ID: 26928966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful Treatment of T Cell-Mediated Acute Rejection with Delayed CTLA4-Ig in Mice.
    Young JS; Khiew SH; Yang J; Vannier A; Yin D; Sciammas R; Alegre ML; Chong AS
    Front Immunol; 2017; 8():1169. PubMed ID: 28970838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Donor apoptotic cell-based therapy for effective inhibition of donor-specific memory T and B cells to promote long-term allograft survival in allosensitized recipients.
    Dangi A; Yu S; Lee FT; Burnette M; Knechtle S; Kwun J; Luo X
    Am J Transplant; 2020 Oct; 20(10):2728-2739. PubMed ID: 32275799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Equal Expansion of Endogenous Transplant-Specific Regulatory T Cell and Recruitment Into the Allograft During Rejection and Tolerance.
    Young JS; Yin D; Vannier AGL; Alegre ML; Chong AS
    Front Immunol; 2018; 9():1385. PubMed ID: 29973932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CTLA4-Ig plus bone marrow induces long-term allograft survival and donor specific unresponsiveness in the murine model. Evidence for hematopoietic chimerism.
    Pearson TC; Alexander DZ; Hendrix R; Elwood ET; Linsley PS; Winn KJ; Larsen CP
    Transplantation; 1996 Apr; 61(7):997-1004. PubMed ID: 8623206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic CD40L blockade is required for long-term cardiac allograft survival with a clinically relevant CTLA4-Ig dosing regimen.
    Unger LW; Muckenhuber M; Mahr B; Schwarz C; Pilat N; Granofszky N; Regele H; Wekerle T
    Front Immunol; 2022; 13():1060576. PubMed ID: 36569922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [CTLA4-Ig prevents corneal allograft rejection in mice].
    Shi WY; Xie LX
    Zhonghua Yan Ke Za Zhi; 2004 Oct; 40(10):696-700. PubMed ID: 16200862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of STAT4 and STAT6 signaling in allograft rejection and CTLA4-Ig-mediated tolerance.
    Zhou P; Szot GL; Guo Z; Kim O; He G; Wang J; Grusby MJ; Newell KA; Thistlethwaite JR; Bluestone JA; Alegre ML
    J Immunol; 2000 Nov; 165(10):5580-7. PubMed ID: 11067913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tracing Donor-MHC Class II Reactive B cells in Mouse Cardiac Transplantation: Delayed CTLA4-Ig Treatment Prevents Memory Alloreactive B-Cell Generation.
    Yang J; Chen J; Young JS; Wang Q; Yin D; Sciammas R; Chong AS
    Transplantation; 2016 Aug; 100(8):1683-91. PubMed ID: 27362308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Memory CD4 T Cells Induce Antibody-Mediated Rejection of Renal Allografts.
    Gorbacheva V; Fan R; Fairchild RL; Baldwin WM; Valujskikh A
    J Am Soc Nephrol; 2016 Nov; 27(11):3299-3307. PubMed ID: 27020853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Donor-Derived Regulatory Dendritic Cell Infusion Maintains Donor-Reactive CD4
    Ezzelarab MB; Lu L; Shufesky WF; Morelli AE; Thomson AW
    Front Immunol; 2018; 9():250. PubMed ID: 29520267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CTLA4-Ig prolongs graft survival specifically in young but not old mice.
    Heinbokel T; Quante M; Iske J; Nian Y; Maenosono R; Minami K; Liu Y; Azuma H; Elkhal A; Tullius SG
    Am J Transplant; 2021 Feb; 21(2):488-502. PubMed ID: 32717114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphoid sequestration of alloreactive memory CD4 T cells promotes cardiac allograft survival.
    Zhang Q; Chen Y; Fairchild RL; Heeger PS; Valujskikh A
    J Immunol; 2006 Jan; 176(2):770-7. PubMed ID: 16393960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aggressive skin allograft rejection in CD28-/- mice independent of the CD40/CD40L costimulatory pathway.
    Ha J; Bingaman AW; Durham MM; Pearson TC; Larsen CP
    Transpl Immunol; 2001 Oct; 9(1):13-7. PubMed ID: 11680567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intermittent antibody-based combination therapy removes alloantibodies and achieves indefinite heart transplant survival in presensitized recipients.
    Shariff H; Tanriver Y; Brown KL; Meader L; Greenlaw R; Mamode N; Jurcevic S
    Transplantation; 2010 Aug; 90(3):270-8. PubMed ID: 20571468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protection of corneal allografts by CTLA4-Ig.
    Gebhardt BM; Hodkin M; Varnell ED; Kaufman HE
    Cornea; 1999 May; 18(3):314-20. PubMed ID: 10336035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CTLA4-Ig prevents alloantibody production and BMT rejection in response to platelet transfusions in mice.
    Gilson CR; Patel SR; Zimring JC
    Transfusion; 2012 Oct; 52(10):2209-19. PubMed ID: 22321003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Critical role of CD4 help in CD154 blockade-resistant memory CD8 T cell activation and allograft rejection in sensitized recipients.
    Wu Z; Wang Y; Gao F; Shen X; Zhai Y; Kupiec-Weglinski JW
    J Immunol; 2008 Jul; 181(2):1096-102. PubMed ID: 18606661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of costimulation by CD28 and CD154 alters the kinetics and cellular characteristics of corneal allograft rejection.
    Ardjomand N; McAlister JC; Rogers NJ; Tan PH; George AJ; Larkin DF
    Invest Ophthalmol Vis Sci; 2003 Sep; 44(9):3899-905. PubMed ID: 12939307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.